BofA warns Fed risks policy mistake with early rate cuts
Bioventus Inc. (NASDAQ:BVS), a medical device company with a market capitalization of $435 million and annual revenue of $568 million, held its 2025 Annual Meeting of Stockholders on Tuesday, June 3. The meeting saw participation from holders of 73,619,248 shares, representing approximately 89.76% of the outstanding shares of Class A and Class B common stock entitled to vote as a single class.
During the meeting, stockholders elected several Class I directors to the Board of Directors, with each director set to serve until the 2026 annual meeting. The elected directors include Robert E. Claypoole, Philip G. Cowdy, Michelle McMurry-Heath, Guido J. Neels, Guy P. Nohra, and Martin P. Sutter. Voting results for the directors showed a majority in favor, with votes ranging from 58,086,800 to 64,865,453 in support, and 162,134 to 6,940,787 votes withheld. Additionally, there were 8,591,661 broker non-votes for each nominee. While the company is currently not profitable, InvestingPro analysts expect it to return to profitability this year.
Stockholders also ratified the appointment of Grant Thornton LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. The ratification received 73,459,057 votes in favor, 149,101 against, and 11,090 abstentions, with no broker non-votes recorded.
This information is based on a press release issued by Bioventus Inc. and filed with the Securities and Exchange Commission.
In other recent news, Bioventus Inc. reported its Q1 2025 earnings, surpassing analyst expectations with an earnings per share (EPS) of $0.06, compared to the forecasted $0.02. The company’s revenue for the quarter was $124 million, marking a 4% decline, although it achieved 5% organic growth. Despite these positive earnings results, the company experienced a 1.85% decline in its stock during premarket trading. Bioventus continues to face challenges, particularly in its international segment, which may affect its future growth prospects. The company maintains a positive outlook, projecting organic revenue growth of 6-8% for the year and plans to nearly double its cash from operations by the year’s end. Additionally, Bioventus announced its expansion into the platelet-rich plasma (PRP) market through a distribution agreement with Apex Biologics, which is expected to enhance its pain treatment offerings. Analyst firms like Craig Hallum and JPMorgan have noted the company’s strategic moves and growth potential, with a focus on new account wins and international business opportunities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.